Mice Lacking Growth Hormone-Releasing Hormone Develop More Aggressive Colon Cancer
GHRH-knockout mice developed significantly more and larger colon tumors with invasive cancer when exposed to carcinogens, suggesting GHRH has a protective anti-inflammatory role.
Quick Facts
What This Study Found
GHRH-deficient mice showed significantly increased tumor number, size, and invasiveness in a colon carcinogenesis model, with elevated COX-2, TNF-α, NF-κB, and iNOS.
Key Numbers
KO: more tumors, larger, distal colon, invasive adenocarcinomas; WT: adenomas only; KO higher PGE2, COX-2, TNF-α, NF-kB, iNOS
How They Did This
GHRH knockout vs wild-type mice treated with AOM/DSS chemical carcinogenesis protocol. Endpoints: tumor count/size, histopathology, Disease Activity Index, inflammatory marker gene expression, PGE2 and 8-iso-PGF2α levels.
Why This Research Matters
This challenges the simplistic view that growth hormone signaling always promotes cancer. GHRH may actually protect against inflammation-driven cancers, which has implications for anti-aging interventions that suppress the somatotropic axis.
The Bigger Picture
The growth hormone axis is a double-edged sword in cancer. While GH/IGF-1 excess may promote some cancers, this study shows complete GHRH absence worsens inflammation-associated carcinogenesis — important for the longevity field that targets GH reduction.
What This Study Doesn't Tell Us
Male mice only; cannot distinguish whether effects are from GHRH loss or secondary GH deficiency; group sizes not specified; chemical carcinogenesis model may not fully represent human colon cancer.
Questions This Raises
- ?Is the cancer-promoting effect due to missing GHRH directly or the resulting GH deficiency?
- ?Would GHRH replacement therapy restore the protective effect?
- ?Do humans with GH deficiency have increased colon cancer risk?
Trust & Context
- Key Stat:
- Invasive vs non-invasive GHRH-/- mice developed invasive adenocarcinomas while wild-type mice only developed benign adenomas
- Evidence Grade:
- Moderate — well-designed knockout mouse study with multiple endpoints, but unspecified group sizes and male-only design.
- Study Age:
- Published in 2020; the relationship between the GH axis and cancer continues to be debated.
- Original Title:
- Growth hormone-releasing hormone (GHRH) deficiency promotes inflammation-associated carcinogenesis.
- Published In:
- Pharmacological research, 152, 104614 (2020)
- Authors:
- Leone, Sheila(6), Chiavaroli, Annalisa(5), Recinella, Lucia(5), Di Valerio, Valentina, Veschi, Serena, Gasparo, Irene, Bitto, Alessandra, Ferrante, Claudio, Orlando, Giustino, Salvatori, Roberto, Brunetti, Luigi
- Database ID:
- RPEP-04941
Evidence Hierarchy
Frequently Asked Questions
Doesn't growth hormone promote cancer?
It's complicated. Excess GH/IGF-1 may fuel some cancers, but this study shows that completely lacking GHRH actually worsened inflammation-driven colon cancer — suggesting a protective role at normal levels.
What is AOM/DSS?
A standard lab protocol combining a chemical carcinogen (AOM) with an intestinal irritant (DSS) to induce inflammation-associated colon tumors in mice.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04941APA
Leone, Sheila; Chiavaroli, Annalisa; Recinella, Lucia; Di Valerio, Valentina; Veschi, Serena; Gasparo, Irene; Bitto, Alessandra; Ferrante, Claudio; Orlando, Giustino; Salvatori, Roberto; Brunetti, Luigi. (2020). Growth hormone-releasing hormone (GHRH) deficiency promotes inflammation-associated carcinogenesis.. Pharmacological research, 152, 104614. https://doi.org/10.1016/j.phrs.2019.104614
MLA
Leone, Sheila, et al. "Growth hormone-releasing hormone (GHRH) deficiency promotes inflammation-associated carcinogenesis.." Pharmacological research, 2020. https://doi.org/10.1016/j.phrs.2019.104614
RethinkPeptides
RethinkPeptides Research Database. "Growth hormone-releasing hormone (GHRH) deficiency promotes ..." RPEP-04941. Retrieved from https://rethinkpeptides.com/research/leone-2020-growth-hormonereleasing-hormone-ghrh
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.